Get the Stockscreener App
109.56
1.33%
-1.48
After Hours:
108.60
-0.96
-0.88%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $109.56, with a volume of 11.06M.
It is down -1.33% in the last 24 hours and down -1.15% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$111.04
Open:
$110.72
24h Volume:
11.06M
Relative Volume:
1.25
Market Cap:
$190.38B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
29.48
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-5.84%
1M Performance:
-1.15%
6M Performance:
-17.59%
1Y Performance:
-18.89%
1-Day Range:
$108.34
$110.72
1-Week Range:
$108.34
$115.85
52-Week Range:
$105.27
$139.15
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
109.56 | 192.95B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
364.56 | 141.79B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
90.90 | 119.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
71.35 | 108.31B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.64 | 48.72B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Volatility - simplywall.st
Abbott IP chief: ‘Firms without AI policies scare me’ - Life Sciences Intellectual Property Review
Abbott Laboratories $ABT Shares Sold by Victory Capital Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Abbott Faces Trial Over Claims Its Infant Formula Caused Bowel Disease in Premature Babies - The Indian Practitioner
Trial over Abbott Laboratories’ formula for premature babies set to begin this week - Times West Virginian
Crossmark Global Holdings Inc. Purchases 12,373 Shares of Abbott Laboratories $ABT - MarketBeat
Respiratory Disease Testing Market Global Forecast Report 2026-2032: $9.32 Bn Opportunities in Integrating Advanced Diagnostics, Leveraging Partnerships, and Enhancing Supply Resilience - GlobeNewswire Inc.
Abbott Labs to face trial on infant formula - The Economic Times
Trial over Abbott Laboratories’ formula for premature babies set to begin in Chicago this week - The Daily Gazette
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Daywatch: Trial over Abbott Laboratories’ formula for premature babies set to begin - Chicago Tribune
Abbott set to face trial over claims premature infant formula caused deadly disease - Reuters
Trial over Abbott Laboratories’ formula for premature babies set to begin in Cook County this week - Chicago Tribune
Dimensional Fund Advisors LP Purchases 169,115 Shares of Abbott Laboratories $ABT - MarketBeat
US002824BU37 Bond Price and Chart — SWB:US002824BU37 - TradingView
Abbott Laboratories EVP Cushman sells $30k in stock By Investing.com - Investing.com Australia
Abbott Laboratories EVP Cushman sells $30k in stock - Investing.com South Africa
A4EQ5K Bond Price and Chart — GETTEX:A4EQ5K - TradingView
Insider Selling: Abbott Laboratories (NYSE:ABT) EVP Sells 613 Shares of Stock - MarketBeat
Abbott Laboratories (NYSE:ABT) EVP Sells $102,288.30 in Stock - MarketBeat
Insider Selling: Abbott Laboratories (NYSE:ABT) EVP Sells 263 Shares of Stock - MarketBeat
Insider Sell: Elizabeth Cushman Sells Shares of Abbott Laborator - GuruFocus
Abbott (ABT) SVP Eric Shroff logs share sale and tax disposition - Stock Titan
Abbott Laboratories (ABT) EVP logs 4,997-share tax-withholding disposition on Form 4 - Stock Titan
Abbott (NYSE: ABT) EVP logs share sale and tax disposition - Stock Titan
Abbott (NYSE: ABT) EVP Morrone logs stock sale and tax share disposition - Stock Titan
Abbott Laboratories (ABT) EVP logs tax-withholding disposition of 8,577 shares - Stock Titan
[Form 4] ABBOTT LABORATORIES Insider Trading Activity - Stock Titan
Abbott Laboratories (ABT) CFO uses 7,441 shares to cover tax withholding - Stock Titan
Abbott (ABT) EVP logs stock sale and tax-withholding share disposal - Stock Titan
How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story - Yahoo Finance
Abbott Labs Finishes Off Suit Over Google, Meta Data Sharing - Bloomberg Law News
Abbott Laboratories Spent $20 Billion to Enter Cancer Diagnostics: Why Analysts See 60% Upside - TIKR.com
Exact Sciences Holders Back Abbott Deal As Valuation Gap Draws Focus - simplywall.st
Better Value & Growth: STE, RMD Lead Abbott Laboratories Stock - Trefis
Abbott Laboratories Stock: Is This Quiet Health Tech Giant Your Next Big US Play? - AD HOC NEWS
Abbott Beats Data Sharing Suit Over Glucose Tracking Trial - Law360
Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Share Price Weakness? - simplywall.st
[144] ABBOTT LABORATORIES SEC Filing - Stock Titan
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Futures Contracts for Abbott Laboratories Futures - TradingView
NICE recommends leadless pacemakers to treat slow heart rhythms - BioWorld MedTech
2 Reasons to Like ABT and 1 to Stay Skeptical - StockStory
Abbott wins FDA approval for updated heart failure monitoring device - MedTech Dive
Abbott Laboratories (NYSE:ABT) Emerges as a Top Dividend Stock with Strong Fundamentals - ChartMill
Fisher Asset Management LLC Raises Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Laurel Wealth Advisors LLC - MarketBeat
Abbott Laboratories stock forecast for 2030: Exact Sciences acquisition reshapes growth outlook toward $180 - Traders Union
Antibiotics Market - GlobeNewswire Inc.
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):